MarketPeel
Insider Trading Intelligence
Pricing
…
RS

Richard I. Steinhart

BTAI
CHIEF FINANCIAL OFFICER · BIOXCEL THERAPEUTICS, INC. · CIK 0001293789
FILING MIX · LIFETIME55%/45%
BUYS
53
SELLS
44
TOTAL VALUE
$393.0K
COMPANIES
3
ACTIVE SINCE
May 2020
HOLDINGS NOW
10,212
AVG SELL PX
$13.67
TRADE KIND
SHOWING 97 / 97
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
9 backtested trades · 8 horizons · 4 pending
Forward-return performance of every backtestable P/S trade by Richard I. Steinhart, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d9+77.78%-5.57%+0.72%-6.28%-10.05%—
14d9+77.78%-7.42%+0.69%-8.11%-6.99%—
30d9+88.89%-7.23%+1.75%-8.98%-10.75%—
60d9+88.89%-33.22%+4.37%-37.60%-40.05%—
90d9+88.89%-47.54%+4.81%-52.35%-55.09%—
180d9+100.00%-74.58%+6.84%-81.42%-79.84%—
1y9+100.00%-79.73%+17.48%-97.22%-89.86%—
2y9(4 pending)+100.00%-86.76%+34.77%-121.54%-131.70%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BTAI · 212 shares · as of Jun 15, 2026
067,500135,000202,500270,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 53 buys / 44 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
35——212Jun 15, 2026Jun 17, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
35——26,335Jun 15, 2026Jun 17, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,845$1.09$7.4K26,300May 20, 2026May 22, 2026 ↗View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,000——10,000May 12, 2026May 14, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
17,500——33,145May 4, 2026May 22, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
17,500——52,500May 4, 2026May 22, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
9,000——0May 1, 2026May 7, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
9,000——15,645May 1, 2026May 7, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
35——6,645Mar 15, 2026Mar 16, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
35——247Mar 15, 2026Mar 16, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
33——97Mar 14, 2026Mar 16, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
33——6,610Mar 14, 2026Mar 16, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,000——70,282Jan 1, 2026Jan 5, 2026 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
35——282Dec 15, 2025Dec 15, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
35——6,577Dec 15, 2025Dec 15, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
33——6,542Dec 14, 2025Dec 15, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
33——130Dec 14, 2025Dec 15, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
35——6,509Sep 15, 2025Sep 16, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
35——317Sep 15, 2025Sep 16, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
33——163Sep 14, 2025Sep 16, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
33——6,474Sep 14, 2025Sep 16, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,000——9,000Aug 1, 2025Aug 5, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
625——6,441Jul 22, 2025Jul 22, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
625——0Jul 22, 2025Jul 22, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,375——5,816Jul 22, 2025Jul 22, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
35——352Jun 15, 2025Jun 16, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
35——1,441Jun 15, 2025Jun 16, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
33——196Jun 14, 2025Jun 16, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
33——1,406Jun 14, 2025Jun 16, 2025 ↗View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000——125,000May 15, 2025May 16, 2025 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
SALE
8,333——0Mar 31, 2025Apr 2, 2025 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
SALE
18,351——0Mar 31, 2025Apr 2, 2025 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
SALE
72,156——0Mar 31, 2025Apr 2, 2025 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
SALE
8,333——0Mar 31, 2025Apr 2, 2025 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
SALE
70,311——0Mar 31, 2025Apr 2, 2025 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
SALE
2,500——0Mar 31, 2025Apr 2, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
34——1,373Mar 15, 2025Mar 17, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
34——387Mar 15, 2025Mar 17, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
31——229Mar 14, 2025Mar 17, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
31——1,339Mar 14, 2025Mar 17, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
270,000——270,000Jan 7, 2025Jan 10, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
205$0.36$7421,157Dec 16, 2024Dec 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
372$0.36$13320,932Dec 16, 2024Dec 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
562——5,064Dec 15, 2024Dec 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
562——21,362Dec 15, 2024Dec 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
521——20,800Dec 14, 2024Dec 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
521——2,606Dec 14, 2024Dec 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,175$0.55$3.9K20,279Oct 3, 2024Oct 3, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,250——27,454Sep 17, 2024Oct 3, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
356$0.69$2466,204Sep 16, 2024Sep 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
563——5,625Sep 15, 2024Sep 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
563——6,560Sep 15, 2024Sep 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
521——5,997Sep 14, 2024Sep 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
521——3,127Sep 14, 2024Sep 17, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
625——625Jul 22, 2024Apr 1, 2025 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,875——1,875Jul 22, 2024Apr 1, 2025 ↗View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000——125,000Jun 27, 2024Jul 1, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
372$1.26$4705,476Jun 17, 2024Jun 18, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
562——6,188Jun 15, 2024Jun 18, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
562——5,848Jun 15, 2024Jun 18, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
521——3,648Jun 14, 2024Jun 18, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
521——5,286Jun 14, 2024Jun 18, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,069$2.64$2.8K4,765Apr 4, 2024Apr 8, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
2,250——5,834Mar 15, 2024Apr 8, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,250——6,750Mar 15, 2024Apr 8, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
521——4,169Mar 14, 2024Apr 8, 2024 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
521——3,584Mar 14, 2024Apr 8, 2024 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
70,311——70,311Dec 28, 2023Dec 29, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
521——4,690Dec 14, 2023Dec 18, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
521——3,063Dec 14, 2023Dec 18, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
521——2,542Sep 14, 2023Sep 18, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
521——5,211Sep 14, 2023Sep 18, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
521——2,021Jun 14, 2023Jun 16, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
521——5,732Jun 14, 2023Jun 16, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,000$27.17$135.9K1,500May 15, 2023May 16, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
5,000——0May 14, 2023May 16, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
5,000——6,500May 14, 2023May 16, 2023 ↗View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000——125,000May 4, 2023May 5, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
32,000——32,000Mar 15, 2023Mar 16, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,000——9,000Mar 15, 2023Mar 16, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,084$19.50$40.6K1,500Mar 15, 2023Mar 16, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
2,084——3,584Mar 14, 2023Mar 16, 2023 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,084——6,253Mar 14, 2023Mar 16, 2023 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
72,156——72,156Jul 1, 2022Jul 1, 2022 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,000——5,000May 14, 2022May 17, 2022 ↗View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,000——500,000May 13, 2022May 16, 2022 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,337——8,337Mar 14, 2022Mar 16, 2022 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
33,350——33,350Mar 14, 2022Mar 16, 2022 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
18,351——18,351Sep 1, 2021Sep 3, 2021 ↗View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,000——50,000May 14, 2021May 18, 2021 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Mar 25, 2021Mar 29, 2021 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASE
Chief Financial Officer
3,750$5.55$20.8K5,250Feb 1, 2021Feb 3, 2021 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,750$48.15$180.6K1,500Feb 1, 2021Feb 3, 2021 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,750——80,148Feb 1, 2021Feb 3, 2021 ↗View →
ATNM
ACTINIUM PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
8,333——8,333Aug 12, 2020Aug 14, 2020 ↗View →
BTAI
BIOXCEL THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
55,000——55,000May 26, 2020May 28, 2020 ↗View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
45,000——45,000May 15, 2020May 19, 2020 ↗View →
Other insiders · BTAI
Loading peer insiders…
About this filer
CIK 0001293789
ROLE
Chief Financial Officer
PRIMARY
BTAI
COMPANIES
3
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001293789DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback